Future prospects of Leishmaniasis Treatment market forecast by 2021 to 2028 with in-depth analysis of key players – Sanofi SA, Sequus Pharmaceuticals Inc., Paladin Labs Inc.
According to the World Health Organization (WHO), approximately 7,000,000 to 1 million new cases and 20,000 to 30,000 deaths occur worldwide each year from leishmaniasis. There are three types of leishmaniasis, namely cutaneous-mucous leishmaniasis, visceral leishmaniasis and cutaneous leishmaniasis. Visceral leishmaniasis (VL) is the most serious disease among the other two forms of leishmaniasis. According to the World Health Organization (WHO), approximately 50,000 to 90,000 new cases of visceral leishmaniasis occur each year worldwide. According to the WHO, in 2015, more than 90% of new cases of visceral leishmaniasis were from Kenya, Somalia, Ethiopia, India, Brazil, Sudan and South Sudan, creating a greatest opportunity for leishmaniasis treatment Marlet. The prevalence of cutaneous leishmaniasis in North and South America, the Middle East, Central Asia and the Mediterranean basin is around 95%, according to the WHO fact sheet from April 2017. people infected with leishmaniasis develop several symptoms, such as fever, weight loss, sores on the skin, nose, mouth or throat, enlarged spleen and liver, and abnormal blood tests. Some patients have symptoms of anemia, leukopenia and thrombocytopenia. The geriatric population, infants, pregnant or breastfeeding women and people infected with HIV have a high risk of contracting leishmaniasis infections, due to their weak immune system.
Leishmaniasis, also known as Lassa fever, is an infectious disease of the lymphatic system that results from infection with leishmaniasis parasites. It is spread to humans through the bite of sandflies carrying leishmaniasis, which are widespread in parts of the Western Pacific, Central Asia, South Africa, India and Sri Lanka. These parasites are transmitted through insect bites, blood transfusions, and infected rashes. Recent estimates indicate that there are around twenty-four million new cases of leishmaniasis each year in the United States alone, mainly in the Middle East and Southeast Asia. Leishmaniasis is considered one of the most neglected tropical diseases, with less than one percent of physicians performing dermatologic surgery. For this reason, leishmaniasis has not been included in the lists of curable tropical diseases, and the only way to prevent serious health problems is to avoid contact with infected animals or their wastes.
Request a PDF brochure with the latest information here @ https://www.coherentmarketinsights.com/insight/request-pdf/932
Leishmaniasis Treatment Market Taxonomy:
On the basis of disease type, the Leishmaniasis Treatment market is segmented into:
- Cutaneous leishmaniasis
- Visceral leishmaniasis
- Mucocutaneous leishmaniasis
On the basis of drug type, the leishmaniasis treatment market is segmented into:
- Pentavalent antimony
- Sodium stibogluconate
- SSG Meglumine Antimoniate
- Amphotericin B
- Liposomal Amphotericin B
Advent of New Chemical Entity Drives Growth of Leishmaniasis Treatment Market
Advances in drug discovery are expected to drive the growth of the leishmaniasis treatment market. According to data published in 2017, by the Drugs for Neglected Diseases (DNDi ‘) initiative, two new chemical entities (NCEs) DNDI-6148 and DNDI-0690 are being introduced in preclinical development to treat visceral and cutaneous leishmaniasis in 2016 Immunomodulator – CpG-D35 is also in the preclinical development phase, which will be used in addition to drug treatment to combat cutaneous leishmaniasis.
Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/932
Agreement between WHO and Gilead Sciences, Inc. to expand the leishmaniasis treatment market
In 2016, the World Health Organization (WHO) and Gilead Sciences, Inc. signed an agreement to donate 3,80,400 vials of AmBisome (liposomal amphotericin B), extending their previous agreement from 2016 to 2021. The collaboration and five-year funding of US $ 20 million from Gilead Sciences, Inc. is intended to provide access to diagnosis and treatment to populations affected by visceral leishmaniasis in major endemic countries such as Ethiopia, India, Nepal, Bangladesh, South Sudan and Sudan. The financial contribution from Gilead Sciences, Inc. has helped WHO expand, monitor and strengthen surveillance in many endemic countries.
Key players in the leishmaniasis treatment market
The major players engaged in the Leishmaniasis Treatment market include Sanofi SA, Sequus Pharmaceuticals Inc., Paladin Labs Inc., Enzon Pharmaceuticals Inc., Gland Pharma Limited and Lifecare Innovations Private Limited.
Reasons to buy this report
• Current and future outlook of the global leishmaniasis treatment market in developed and emerging markets
• The segment which is expected to dominate the market as well as the segment which holds the highest CAGR during the forecast period.
• Regions / countries expected to experience the fastest growth rates during the forecast period
• The latest developments, market shares and strategies used by the main market players
Access research reports designed specifically for you and your organization to explore practical growth strategies and recommendations
To purchase this Premium Research Report directly: https://www.coherentmarketinsights.com/insight/buy-now/932
Chapter 1 Industry overview
1.3 Scope of the research
1.4 Market Analysis by Regions
1.5 Analysis of Leishmaniasis Treatment Market Size from 2021 to 2028
11.6 COVID-19 outbreak: impact on the leishmaniasis treatment industry
Chapter 2 Global Leishmaniasis Treatment Competition by Types, Applications and Major Regions and Countries
2.1 Global Leishmaniasis Treatment (Volume & Value) by Type
2.3 Global Leishmaniasis Treatment (Volume & Value) by Regions
chapter 3 Production market analysis
3.1 Global Production Market Analysis
3.2 Regional production market analysis
Chapter 4 Global Leishmaniasis Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Leishmaniasis Treatment Market Analysis
Chapter 6 East Asia Leishmaniasis Treatment Market Analysis
Chapter 7 Analysis of the leishmaniasis treatment market in Europe
Chapter 8 South Asia Leishmaniasis Treatment Market Analysis
Chapter 9 Southeast Asia Leishmaniasis Treatment Market Analysis
Chapter 10 Middle East Leishmaniasis Treatment Market Analysis
Chapter 11 Africa Leishmaniasis Treatment Market Analysis
Chapter 12 Analysis of the leishmaniasis treatment market in Oceania
Chapter 13 South America Leishmaniasis Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures of the Leishmaniasis Treatment Industry
Chapter 15 Global Leishmaniasis Treatment Market Forecast (2021-2027)
Chapter 16 Conclusion
Coherent Market Insights is a global market intelligence and consulting organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office in India, an office at Global Financial Capital in the United States, and business consultants in the United Kingdom and Japan. Our clientele includes players from various industries in more than 150 countries around the world. We pride ourselves on serving clients the full length and breadth of the horizon, from Fortune 500 companies to nonprofits and startups looking to gain a foothold in the market. We excel in delivering unmatched actionable market insights across a variety of industry verticals, including chemicals and materials, healthcare, food and beverage, consumer goods, packaging, semiconductors, software and services, telecommunications and automotive. We offer syndicated market intelligence reports, customized research solutions and advisory services.
Consistent market information
1001 4th Ave, # 3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: + 1-206-701-6702
United Kingdom: + 44-020-8133-4027
Japan: + 050-5539-1737
India: + 91-848-285-0837